Matica Bio will produce viral vectors at its GMP facility, while CytoImmune will manufacture its cell therapy at its Puerto Rico facility for IND submission.
Mark Gaffney offers 20+ years of experience in corporate strategy, business development, and operations in both private and public biotechnology companies.